Drugs / Telaglenestat
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03965845 | Jun 2019 → Sep 2021 | non-small cell lung carcinoma | Calithera Biosciences, Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telaglenestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965845 ↗ |
| Known as | CB-839 | “Telaglenestat (CB-839)” NCT03965845 ↗ |
| Action | Inhibit | “glutaminase inhibitor telaglenestat (CB-839)” NCT03965845 ↗ |
| Route | Oral | “Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level” NCT03965845 ↗ |